Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Expected to Post Q3 2024 Earnings of $0.24 Per Share

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Rating) – Research analysts at William Blair issued their Q3 2024 EPS estimates for shares of Eagle Pharmaceuticals in a research note issued to investors on Monday, March 13th. William Blair analyst T. Lugo anticipates that the specialty pharmaceutical company will post earnings per share of $0.24 for the quarter. The consensus estimate for Eagle Pharmaceuticals’ current full-year earnings is $1.71 per share.

A number of other analysts have also commented on EGRX. StockNews.com lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Piper Sandler reduced their price target on shares of Eagle Pharmaceuticals from $41.00 to $31.00 in a research note on Tuesday.

Eagle Pharmaceuticals Stock Up 2.8 %

NASDAQ:EGRX opened at $26.47 on Thursday. The firm has a 50-day simple moving average of $30.34 and a two-hundred day simple moving average of $30.94. Eagle Pharmaceuticals has a fifty-two week low of $23.87 and a fifty-two week high of $52.22. The firm has a market cap of $344.64 million, a P/E ratio of 8.76 and a beta of 0.92. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.99 and a current ratio of 1.70.

Institutional Trading of Eagle Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. State of Tennessee Treasury Department grew its stake in shares of Eagle Pharmaceuticals by 4.1% in the fourth quarter. State of Tennessee Treasury Department now owns 8,345 shares of the specialty pharmaceutical company’s stock worth $244,000 after acquiring an additional 328 shares during the period. Lazard Asset Management LLC boosted its holdings in shares of Eagle Pharmaceuticals by 8.6% in the fourth quarter. Lazard Asset Management LLC now owns 4,703 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 373 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Eagle Pharmaceuticals by 1.5% in the fourth quarter. Legal & General Group Plc now owns 26,857 shares of the specialty pharmaceutical company’s stock worth $785,000 after buying an additional 400 shares during the last quarter. Summit Global Investments boosted its holdings in shares of Eagle Pharmaceuticals by 1.7% in the third quarter. Summit Global Investments now owns 34,325 shares of the specialty pharmaceutical company’s stock worth $907,000 after buying an additional 587 shares during the last quarter. Finally, Martingale Asset Management L P boosted its holdings in shares of Eagle Pharmaceuticals by 4.6% in the third quarter. Martingale Asset Management L P now owns 14,756 shares of the specialty pharmaceutical company’s stock worth $391,000 after buying an additional 651 shares during the last quarter. 88.09% of the stock is currently owned by institutional investors.

Eagle Pharmaceuticals Company Profile

(Get Rating)

Eagle Pharmaceuticals, Inc is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L.